Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against mycobacterium tuberculosis in C57BL/6 mice

Tubercle and Lung Disease

Volumn 77, Issue 2, 1996, Pages 154-159

  Reddy, M V ^a   Luna Herrera, J ^a   Daneluzzi, D ^a   Gangadharam, P R J ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOXAZINORIFAMYCIN; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LUNG; MALE; MORTALITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; SPLEEN; TUBERCULOSIS;

EID: 0029881154     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(96)90030-1     Document Type: Article

References (9)

1. Kuze F, Yamamoto T, Amitani R, Suzuki K. In vivo activities of new rifamycin derivatives against mycobacteria. Kekkaku 1990; 66: 7-12.
2. Saito H, Tomioka H, Sato K et al. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother 1991; 35: 542-547.
3. Tomioka H, Saito H, Sato K et al. Chemotherapeutic efficacy of newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1992; 36: 387-393.
4. Saito H, Tomioka H, Sato K, Kawahara S, Hidaka T, Dekio S. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tubercle Lung Dis. 1995; 76: 51-58.
5. Luna-Herrera J, Reddy M. V, Gangadharam P R J. In vitro activity of benzoxazinorifamycin KRM-1648 against drug susceptible and multi-drug resistant tubercle bacilli. Antimicrob Agents Chemother 1995; 39: 440-444.
6. Klemens S P, Grossi M A, Cynamon M H. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in murine model. Antimicrob Agents Chemother 1994; 38: 2245-2248.
7. Kanyok T P, Reddy M V, Chinnaswamy J, Danziger L H, Gangadharam P R J. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents. Chemother 1994; 38: 170-173.
8. Sirgel F A, Botha F J H, Parkin D P et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob. Chemother 1993; 2: 867-875.
9. Middlebrook G, Cohn M L. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953; 118: 297-299.